Background: Data on genetic markers that determine the prognosis of multiple sclerosis (MS) is still limited. The association between galanin gene polymorphism rs948854 and prognosis of MS had been demonstrated earlier.
Objectives: To confirm earlier findings in a distinct from the previously studied cohort of patients, and to further characterized the rs948854 polymorphism as one of the candidates for the risk stratification in patients with MS.
Methods: To assess the rate of disease progression, the MS severity score (MSSS) and Age Related Multiple Sclerosis Severity (ARMSS) score were used, along with the Progression Index (PI).
Results: The significant association of a minor allele of rs948854 polymorphism with the severity of the course of multiple sclerosis was revealed, confirming earlier findings. An increase in the proportion of patients with a MSSS > 5 (high rate of progression) was observed among the minor G allele carriers (genotypes AG and GG) compared to patients with AA genotype. Furthermore, the age at onset correlated with the MSSS value only in the group of minor allele carriers and the effect of a minor allele appeared only in patients with the late age at onset (>30 years).
Conclusion: Collectively, our data support the contribution of galanin gene polymorphism rs948854 to the mechanisms of adverse course of the disease in the late onset MS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.msard.2019.101439 | DOI Listing |
Mitochondrion
December 2024
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS). The etiology of MS remains elusive, with a complex interplay of genetic and environmental factors contributing to its pathogenesis. Recent studies showed mitochondrial DNA (mtDNA) as a potential player in the development and progression of MS.
View Article and Find Full Text PDFMult Scler Relat Disord
December 2024
Laboratory of Nuclear Medicine (LIM43), Department of Radiology and Oncology, Faculdade de Medicina-FMUSP, Universidade de São Paulo, São Paulo 05403-911, SP, Brazil. Electronic address:
Background: Multiple sclerosis (MS) is divided into Relapsing-Remitting (RRMS) and Progressive (PMS) phenotypes, both associated with spinal cord (SC) damage. MS-related disability and SC atrophy are not yet fully understood and can differ across phenotypes. A combined approach using Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) could provide a broader understanding of myelin changes in the cervical SC (CSC) in different MS phenotypes and the associations with disability.
View Article and Find Full Text PDFMult Scler Relat Disord
December 2024
Kahramanmaras Sutcu Imam University, Faculty of Medicine, Department Of Neurology, Onikisubat, Kahramanmaras, Turkey. Electronic address:
Backround: Manual therapy techniques are available for pain management in Multiple Sclerosis (MS); however, the results of neurodynamic mobilization (NM) are not known. The aim of this study was to investigate the effects of NM exercises on pain, muscle strength and upper extremity functions in MS patients.
Methods: Patients aged between 18 and 65 years diagnosed with Relapsing Remitting (RR) MS (n = 31) according to McDonald 2010 diagnostic criteria were included in the study.
J Neuroimmunol
December 2024
Versiti Blood Research Institute, Milwaukee, WI, USA; Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address:
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Smolensk State Medical University, Smolensk, Russia.
Objective: To study the quality of life (QoL) of patients with multiple sclerosis (MS) in the Smolensk region who receive MS disease-modifying therapies (DMT).
Material And Methods: The study included 37 patients receiving MS DMT. The 36-Item Short Form Health Survey (SF-36), the Multiple sclerosis Quality of Life (MusiQol), the Hamilton Depression Rating Scale, a scale of satisfaction with treatment, the Fatigue Severity Scale were administered.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!